Cancer Research Horizons and biotech company Turbine have announced a partnership to solve complex diseases. The partnership will utilise Turbine’s Simulated Cells platform to identify target patient populations who could benefit from CDC7 inhibitor therapy with Cancer Research Horizons’ lead compound CRT’2199. CRT’2199 originates from Cancer Research Horizons’ Therapeutic Innovation. Read More
A novel immunotherapy combination, targeting checkpoints in both T cells and myeloid suppressor cells, has significantly improved anti-tumour responses in preclinical models of pancreatic cancer. In the study, published in Nature Cancer, researchers at The University of Texas MD Anderson Cancer Center… Read More
Mersana Therapeutics and a subsidiary of Merck have entered a research collaboration to discover novel Immunosynthen antibody-drug conjugates (ADCs) directed against up to two targets. Under the terms of the agreement, Mersana will develop novel ADC product candidates against up to two targets utilising its Immunosynthen platform to conjugate proprietary… Read More
Janssen has submitted a marketing authorisation application (MAA) seeking approval of talquetamab in Europe for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). Talquetamab is an investigational, off-the-shelf, bispecific T-cell engager antibody targeting both GPRC5D, a novel drug target that is on some normal… Read More
A new drug based on the active ingredient Lutetium-177 PSMA-617 has been approved by the European Commission for the treatment of metastatic prostate cancer carrying the surface molecule PSMA (prostate specific membrane antigen). The drug was developed under the leadership of the German Cancer Research Center (DKFZ)… Read More
The acidity of tumours impairs the effectiveness of anti-cancer therapies, according to a new study that could lead to a new generation of immunotherapy treatments. Tumours have a more acidic environment (pH 6.5) than normal, healthy tissues (pH 7.2). New research has shown for the first time… Read More
Kite and Arcellx have entered a global strategic collaboration to co-develop and co-commercialise CART-ddBCMA for the treatment of patients with relapsed or refractory multiple myeloma. Currently in Phase II clinical development, CART-ddBCMA is an investigational cell therapy product comprising autologous T cells that have been genetically modified… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The focus has been on immunotherapy and genetics this week, with exciting… Read More
News round-up for 12-16 December by DDW Digital Content Editor Diana Spencer. The focus has been on immunotherapy and genetics this week, with exciting developments in the treatment of multiple myeloma, atopic dermatitis, Alzheimer’s, late-stage melanoma and acute myeloid leukaemia. The top stories: … Read More
Clinical biotechnology company Storm Therapeutics has successfully completed a USD $30 million Series B financing round. The investment allows the company to focus on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases. The financing was co-led by existing investors M Ventures,… Read More
Jannsen has revealed clinical trial results for its pipeline of products to treat multiple myeloma and leukaemia. The findings were presented at the American Society of Hematology (ASH) 2022 Annual Meeting taking place in New Orleans, US. Along with positive Phase… Read More
Vor Bio, a clinical-stage cell and genome engineering company, has announced initial clinical data from VBP101, its Phase I/IIa multicentre, open-label, first-in-human study of tremtelectogene empogeditemcel or “trem-cel” (formerly VOR33) in patients with acute myeloid leukaemia (AML). The data observed from the first treated patient support the… Read More
Personalised mRNA vaccine mRNA-4157/V940 has demonstrated a clinically meaningful improvement in patients with late-stage melanoma. The vaccine, in combination with Keytruda, met its primary endpoint of recurrence-free survival (RFS) for the adjuvant treatment of patients with stage III/IV melanoma following complete resection. Adjuvant treatment with… Read More
An immunotherapy that uses a new targeted approach to kill bone marrow cancer cells was successful in as many as 73% of patients in two clinical trials. The trial results have been revealed by researchers from The Tisch Cancer Institute at the Icahn School of Medicine at… Read More
Biometrics contract research organisation (CRO) Phastar has joined Lean Life Science’s Oncology Development Programme (ODP2). The targeted programme aims to identify and accelerate novel oncology innovations into commercially-attractive assets by offering support to academics and early-stage companies. In collaboration with global pharma companies, Cancer Research… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news. ‘Teamwork makes the dream work’ this week, with the launch of… Read More
